Afrezza plus One Drop | Premium
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Oct 5, 2017 → Dec 30, 2019
NCT ID
NCT03313960About Afrezza plus One Drop | Premium
Afrezza plus One Drop | Premium is a approved stage product being developed by MannKind Corp for Diabetes Mellitus, Type 2. The current trial status is unknown. This product is registered under clinical trial identifier NCT03313960. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
4
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03313960 | Approved | UNKNOWN |
Competing Products
20 competing products in Diabetes Mellitus, Type 2